BioSpace News Archive

Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD™ (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and by 83% in the six-month follow-up analysis, compared to placebo.

Jazz Pharmaceuticals plc today announced that it will report its 2022 first quarter financial results on Wednesday, May 4, 2022, after the close of the U.S. financial markets.

Johnson & Johnson will participate in the UBS Global Healthcare Conference on Tuesday, May 24th.

Ampio Pharmaceuticals, Inc. announced the receipt of written responses from the United States Food and Drug Administration pursuant to a Type C meeting request submitted by the Company earlier in the year regarding the AP-013 trial results.

Aerie Pharmaceuticals, Inc. today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., on April 22 through 26, 2022.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief financial officer Laura Clague, CPA, will retire after serving in this role for the past seven years.

Outset Medical, Inc. today announced that it will release financial results for the first quarter of 2022 after the close of trading on Wednesday, May 4, 2022.

Quest Diagnostics today announced it has made several organizational changes and leadership appointments of seasoned executives to better support the company’s two-point business strategy to accelerate growth and drive operational excellence.

Mirati Therapeutics, Inc. will announce financial results for the first quarter of 2022 along with recent corporate updates on May 4, 2022.

Codiak BioSciences, Inc. today announced new preclinical data from its pan beta-coronavirus vaccine program, which aims to protect against all SARS-CoV-2 variants.